ANTIBODY SPECIFICALLY BINDING TO GLP-1R AND FUSION PROTEIN THEREOF WITH GLP-1 Russian patent published in 2019 - IPC C07K16/28 A61K39/395 A61P3/10 C07K19/00 C12N15/09 C12N15/63 

FIELD: biochemistry.

SUBSTANCE: described invention relates to the field of biochemistry. Group of inventions is described that includes an antibody that specifically binds to the glucagon-like peptide receptor 1 (GLP-1R) (versions), a GLP-1 fusion protein, a polynucleotide encoding said GLP-1 fusion protein, an expression vector comprising a polynucleotide, a host cell for producing a GLP-1 fusion protein comprising a vector, a pharmaceutical composition for the prevention or treatment of non-insulin dependent diabetes mellitus in a subject, containing an effective amount of said antibody or GLP-1 fusion protein, a method of preventing or treating non-insulin dependent diabetes mellitus, a method of preventing or treating obesity in a subject, a method of preventing or treating excessive weight in a subject, a method of preventing or treating a disease susceptible to GLP-1R stimulation in a subject, where said methods comprise administering to said antibody or GLP-1 fusion protein or pharmaceutical composition to a subject.

EFFECT: invention widens the range of agents that bind to the glucagon-like peptide receptor 1 (GLP-1R).

53 cl, 6 dwg, 16 ex